Crinetics Pharmaceuticals demonstrated strong execution across its business with significant progress in its pipeline and financial stability. However, high operational costs, cash usage, and potential challenges in launching PALSONIFY indicate areas of concern.

Company Guidance -

Q3 2025

During the Crinetics Pharmaceuticals second quarter 2025 financial results conference call, the company provided guidance on several key aspects of its operations. The anticipated approval of paltusotine, branded as PALSONIFY, is on track for a September 25 PDUFA date, with the FDA review progressing smoothly. Crinetics highlighted its strong financial position with $1.2 billion in cash, cash equivalents, and investments, and projected cash sufficiency into 2029. For 2025, the company adjusted its net cash used in operations guidance to $340 million to $370 million, down from $340 million to $380 million, reflecting clinical timeline precision and overhead cost management. The commercial launch of PALSONIFY is expected to involve approximately 30 sales representatives, with gradual adoption anticipated due to infrequent endocrinologist visits by acromegaly patients. The company also discussed ongoing pivotal programs, including the Phase III trial of paltusotine for carcinoid syndrome and atumelnant for congenital adrenal hyperplasia.

Paltusotine NDA Review on Track

The paltusotine NDA review remains on track with the FDA, with an anticipated approval in September 2025. The regulatory team has maintained strong momentum and confidence in the preparations for the launch.

Strong Financial Position

Crinetics ended the quarter with $1.2 billion in cash, cash equivalents, and investments, providing sufficient funding into 2029 to support operations and multiple value-creating milestones.

Progress in Pipeline Programs

Crinetics is making progress on multiple pipeline programs including trials for carcinoid syndrome and congenital adrenal hyperplasia, with potential new therapies in the pipeline.

Successful Engagement at Medical Conferences

Crinetics had a significant presence at several medical conferences, delivering presentations that highlighted the differentiation of their pipeline and engaging with key opinion leaders.

Record-Level Research and Development Investment

Research and development expenses increased to $80.3 million in Q2, reflecting continued investment in multiple clinical programs.

Crinetics Pharmaceuticals (CRNX) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

CRNX Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 06, 2025	2025 (Q3)	-1.23 / -	-0.96	―	―	―
Aug 07, 2025	2025 (Q2)	-1.08 / -1.23	-0.94	-30.85% (-0.29)	―
May 08, 2025	2025 (Q1)	-0.94 / -1.04	-0.93	-11.83% (-0.11)	―
Feb 27, 2025	2024 (Q4)	-0.89 / -0.88	-0.9	2.22% (+0.02)	―
Nov 12, 2024	2024 (Q3)	-0.91 / -0.96	-1.01	4.95% (+0.05)	―
Aug 08, 2024	2024 (Q2)	-0.86 / -0.94	-0.94	0.00% (0.00)	―
May 09, 2024	2024 (Q1)	-0.81 / -0.93	-0.85	-9.41% (-0.08)	―
Feb 28, 2024	2023 (Q4)	-0.86 / -0.90	-0.84	-7.14% (-0.06)	―
Nov 07, 2023	2023 (Q3)	-0.87 / -1.01	-0.78	-29.49% (-0.23)	―	―
Aug 08, 2023	2023 (Q2)	-0.87 / -0.94	-0.81	-16.05% (-0.13)	―	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

CRNX Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 07, 2025	$27.88	$26.85	-3.69%
May 08, 2025	$32.70	$30.68	-6.18%
Feb 27, 2025	$33.21	$35.78	+7.74%
Nov 12, 2024	$58.78	$58.92	+0.24%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Crinetics Pharmaceuticals (CRNX) report earnings?

Crinetics Pharmaceuticals (CRNX) is schdueled to report earning on Nov 06, 2025, TBA (Confirmed).

What is Crinetics Pharmaceuticals (CRNX) earnings time?

Crinetics Pharmaceuticals (CRNX) earnings time is at Nov 06, 2025, TBA (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is CRNX EPS forecast?

CRNX EPS forecast for the fiscal quarter 2025 (Q3) is -1.23.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing